Background {#Sec1}
==========

Osteoarthritis (OA) refers to a syndrome of joint pain accompanied by functional limitation and reduced quality of life. OA has a high prevalence, which is expected to increase due to the aging population and currently affects over 40 million Europeans \[[@CR1]\]. It is one of the leading causes of pain and disability in everyday life worldwide. The severity of knee and hip OA disability has been associated with a significant increase in all-cause mortality and serious cardiovascular disease events due to the avoidance of physical activities that exacerbate symptoms \[[@CR2]\]~.~ The socioeconomic impact is very high due to the enormous and dramatically escalating burden of this disease \[[@CR3]\]. As there is no cure for OA, a multimodal pharmacologic and non-pharmacologic approach followed by joint replacement is recommended by most guidelines. However, non-invasive multimodal approaches often only result in short term improvement or fail altogether. Additional strategies are needed to treat pain and improve joint function while minimizing side effects. Biological effects of electromagnetic fields (EMFs) in tissues were first described by Fukada and Yasuda \[[@CR4]\], who investigated the piezoelectric phenomenon in bone. Electric and electromagnetic potentials were found to not only affect osteogenesis but also have chondroprotective properties \[[@CR5]\]. In animal studies EMFs reduced knee OA lesions \[[@CR6]\] and have the ability to antagonize the catabolic activity of cytokines in cartilage explants \[[@CR5], [@CR7], [@CR8]\]. Other studies indicate that EMFs may affect intracellular calcium concentration triggering proteoglycan synthesis \[[@CR9], [@CR10]\]. EMF therapy has been shown to partially reduce pain and improve mobility for the treatment of OA as compared to placebo \[[@CR2], [@CR4], [@CR11]\]. However, the question whether EMFs should be used as standard therapy for the treatment of OA remains open.

Experimental studies on EMFs are inconsistent with regard to electromagnetic fields, effector cells or tissues and effector responses. Two current reviews follow the same search approach and analyzed the effect of EMF for the treatment of OA as compared to placebo \[[@CR2], [@CR4]\]. The question remains whether EMF is generally a form of therapy suitable for everybody, or whether there are specific patients who might profit from a specific form of EMF therapy. Previous studies have shown that EMFs increase the chondrogenic potential of human mesenchymal stem cells (hMSCs) during chondrogenic differentiation \[[@CR12]\]. Most astonishing was the fact that positive EMF effects occurred here only under suboptimal and not under optimal cellular conditions \[[@CR12]\]. It is not known whether the suboptimal chondrocytes seen in OA respond differently to EMF than healthy chondrocytes. The aim of this study was to compare the effects of EMFs on OA versus non-OA chondrocytes. To our knowledge this is the first approach to specifically address this question. We further investigated whether the effect could be indeed by any EMF or whether a specific EMF is necessary. We hypothesized that specific EMFs would show more effects on degenerated osteoarthritic than on non-osteoarthritic chondrocytes.

Methods {#Sec2}
=======

Cell culture {#Sec3}
------------

Human OA articular cartilage was obtained from adult patients (patient 1-7) during total knee replacement (*n* = 7) (1 male, 6 female; mean age 67; range 58 - 85). Non-OA articular cartilage was obtained from young patients (patient 8-13) during triple arthrodesis performed as salvage procedure for refactory clubfoot (*n* = 3) or from human knee condyles *of deceased patients after trauma devoid of involvement* of the knee harvested within 12 h of death (*n* = 3) (together 5 male, 1 female; mean age 15; range 13 - 20) (Fig. [1](#Fig1){ref-type="fig"}). The study was approved by the Ludwig-Maximilians-University medical center ethics committee. Chondrocytes were isolated by enzymatic treatment using pronase (Roche Diagnostics, Mannheim, Germany) and collagenase (Sigma-Aldrich, St. Louis, MO) and cultured at 37 °C in a humidified atmosphere in Dulbecco's modified Eagle's medium (DMEM)/Hams F-12 (1:1; Biochrom, Berlin, Germany) containing 10% fetal calf serum (PAA, Pasching, Austria), 1% MEM--amino acids (Biochrom, Berlin, Germany), 25 μg/ml ascorbic acid (Sigma-Aldrich, St. Louis, MO), 50 IU/ml penicillin--streptomycin and 0.25 μg/ml Amphotericin B (Biochrom, Berlin, Germany). The medium was changed every second day. At 100% confluence, cells were passaged using 0.05% Trypsin containing 0.02% EDTA (Biochrom, Berlin, Germany) and were expanded in monolayer triple flasks (Nunc, Rosklide, Denmark). Experiments were performed with chondrocytes at passage 2. At day zero, 4 × 10^5^ chondrocytes were lysed in 1 ml TRIzol Reagent (Life Technologies, Carlsbad, CA) and kept at −80 °C for further RNA-analysis. To form pellet cultures (*n* = 10 for each patient), 4 × 10^5^ cells were centrifuged at 150 *g* for 5 min in a 15 ml polypropylene tube (TPP, Trasadingen, Switzerland). All pellet cultures were cultured for 48 h under the same conditions as mentioned above to allow pellet formation. Experiments were started by transferring pellets into 1.5 ml reaction tubes (Eppendorf, Hamburg, Germany), containing 1 ml of medium and sealed by breathe easy sealing membranes (Sigma-Aldrich, Steinheim, Germany). During the experiment 5 pellet cultures per patient (3 pellets for RNA-analyses and 2 pellets for histology and immunohistochemistry (IHC)) were exposed to EMF (5 mT or 8 mT) respectively within a solenoid. The respective control pellet cultures (*n* = 5) from the same patient were cultivated in a second incubator without a solenoid for 7 days, established as control \[[@CR12]\] (Fig. [1](#Fig1){ref-type="fig"}). All experiments were performed for 7 days, with media being changed every second day.Fig. 1Chart of the experiment with 7 OA patients and 6 nonOA patients. During the experiment 5 pellet cultures per patient were exposed to an EMF (5 mT or 8 mT). As control group 5 pellet cultures from the same patient were cultivated in a second incubator without a solenoid for 7 days

Low frequency sinusoidal EMF {#Sec4}
----------------------------

EMFs were generated with a solenoid (FA-P6-K, Neue Magnetodyn, Munich, Germany) combined with a frequency generator (M80, Neue Magnetodyn, Munich, Germany) as described by Mayer-Wagner et al. \[[@CR12]\]. For experiments, pellets were cultured in 1.5 ml Eppendorf-Safe-Lock tube (Eppendorf, Hamburg, Germany) fixed in a tube-rack inside the coil. To allow gas-exchange tubes were closed with a permeable sealing membrane (Sigma-Aldrich, Steinheim, Germany). The EMF waveform was measured with a teslameter (Bell 640, F.W. Bell, Orlando, FL) inside the coil at the position of the pellet cultures.

In this configuration, the magnetic field is in parallel to the long axis of the base of the tube-rack. The electric field induced by the magnetic field in the plane of the pellets can be calculated with good approximation by the following equation: *E* ~*ymax*~ *= 2h*πf*B* ~*x*~ *πf* \[[@CR13]\], where *B* is the peak value of the magnetic flux density, fis its frequency and *h* is the height of the pellets. With the given values the maximum induced electric field is below 2 mV/m.

The particular waveform, amplitude and sinusoidal frequency of 15 Hz have been established previously in vivo \[[@CR14], [@CR15]\] and in vitro \[[@CR12], [@CR16], [@CR17]\]. The homogeneity of the magnetic field within the solenoid was assured by measuring the spatial distribution of the magnetic flux density with a teslameter. The geomagnetic field in the incubator was determined to be 45 μT parallel to the rotation axis of the solenoid. The field (either 5 mT or 8 mT) was applied every 8 h for 45 min during the course of the 7 day experiment. The waveform was a pure sinusoidal wave with a total harmonic distortion \<1%. The 8 mT field was applied in order to use an unspecific field, which has so far not been shown in the literature to induce effects but is still close to the 5 mT field described to produce an effect.

Histology {#Sec5}
---------

Pellet cultures (2 with EMF treatment and 2 without treatment for each patient) were washed in phosphate buffered saline (PBS) pH 7.4, incubated in 5% sucrose in PBS (21 °C, 15 min), dry embedded in Tissue-Tek (Sakura, Zoeterwoude, Netherlands) and frozen at −20 °C. Serial cryosections (8 μm) were prepared by mounting pellet cultures on SuperFrost glass slides (Menzel-Gläser, Braunschweig, Germany). Cryosections were fixed in acetone (AppliChem, Darmstadt, Germany) and dried at room temperature (RT). Serial sections were stained in triplicate with 0.75% safranin-O (Fluka, Buchs, Switzerland) and 0.02% fast green (Chroma, Münster, Germany).

Immunohistochemistry {#Sec6}
--------------------

Pellet sections were fixed in acetone (AppliChem, Darmstadt, Germany) (10 min, RT) and washed in washing buffer (PBS with 0.2% 5 Brij L23 Solution (Sigma-Aldrich, Steinheim, Germany)). After blocking endogenous tissue peroxidase activity with 0.3% H~2~O~2~ (Merck, Darmstadt, Germany) in aqua dest (4 min, RT) pellet sections were treated with 0.25 U/ml chondroitinase AC from *Flavobacterium Heparium* (Sigma-Aldrich, Steinheim, Germany) in PBS (30 min, 37 °C) followed by washing in washing buffer. Afterwards pellet sections were incubated with monoclonal mouse antibodies (mABs) against collagen type I (Sigma-Aldrich, Saint Louis, MO) diluted in 1:2000 in mAB-dilution-soluion (DCS, Hamburg, Germany) or collagen type II (DSHB, University of Iowa, IA) 1:6 in mAB-dilution-solution (30 min, RT). For negative controls the mABs were omitted. Pellet sections were washed in washing buffer and then incubated with a biotinylated horse-anti-mouse IgG (Vector Laboratories, Burlingame, CA) diluted 1:200 in mAB-dilution-solution (30 min, RT). Afterwards pellet sections were incubated with avidin-biotin-peroxidase-complex (ABC) (Vector Laboratories, Burlingame, CA). After repeated washing, the bound mABs were visualized with 3.3 diamino benzidine tetrahydrochlorhide (DAB) (Vector Laboratories, Burlingame, CA) for approximately 4 min without light. The reaction was stopped with aqua dest. And the sections were counterstained with haematoxylin (AppliChem, Maryland, CA) and embedded in Eukitt (O-Kindler, Freiburg, Germany). Representative images were obtained using a PreciPoint M8 microscope (PreciPoint, Freising, Germany) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Histology and Immunohistochemistry (IHC) staining of one OA-patient and one non-OApatient pellet cultures after 5 mT EMF exposition (**b, f, j, n, d, h, l, p**) or without EMF exposition **(a, e, i, m, c, g, k, o**). Safranin-O staining (**a, b, c, d**) and alcian blue staining (**e, f, g, h**) was positive for all pellet cultures. IHC for collagen type II was much more obvious for OA pellet culture after EMF exposition (**j**) and non-OA pellet cultures with and without EMF exposition (**k, l**). IHC for collagen type I of OA pellet cultures (**m, n**) showed a weaker staining than non-OA pellet cultures (**o, p**)

Visual histological grading system {#Sec7}
----------------------------------

The morphology of pellet cultures was graded according to a visual histological grading system for generated neocartilage \[[@CR18]\]. Two independent and blinded observers evaluated each pellet in 3 categories described below and assigned scores ranging from 0 to 3. Categories were added with equal weight to give a total score (Table [1](#Tab1){ref-type="table"}).Table 1Visual histological grading systemABCtotalOA EMF 0 mT1113 EMF 5 mT2215 EMF 8 mT1113Non-OA EMF 0 mT2237 EMF 5 mT2237 EMF 8 mT2237Three categories were evaluated: **A** intensity of safranin-O staining, **B** distance between cells/amount of matrix that was accumulated and **C** cell morphologies represented

Category A: Intensity of safranin-O staining. Each sample was observed with a 10× objective.

Category B: Distance between cells and amount of matrix produced by chondrocytes were assessed with a 20× objective.

Category C: Cell morphology was examined using a 40× objective. A rounded morphology was expected for chondrocytes and the presence of pyknotic or fibroblast morphology was scored as poor cell quality.

RNA isolation {#Sec8}
-------------

Cell pellets were disrupted under frozen conditions with 3000 rpm for 1 min, using a Micro-Dismembrator S (Sartorius, Göttingen, Germany). Total RNA was isolated directly from freeze-milled preparations, using 1 ml QIAzol Lysis Reagent (Qiagen, Hilden, Germany). After addition of 0.2 ml chloroform (Sigma-Aldrich, Steinheim, Germany), samples were shaken and incubated at RT for 10 min. For phase separation, samples were centrifuged at 15000 g for 20 min at 4 °C and the aqueous phase was transferred to a fresh tube.

Total RNA precipitation was performed by mixing 0.5 ml Isopropanol (Sigma-Aldrich, Steinheim, Germany) with the aqueous phase. After incubation at RT for 10 min samples were centrifuged at 15000 g over night at 4 °C. RNA pellets were washed twice with 1 ml 75% Ethanol (Merck, Darmstadt, Germany) and centrifuged at 15000 g for 20 min at RT. After drying pellets, total RNA was dissolved in 32 μl RNAse free water (Gibco, Darmstadt, Germany). Concentration and purity was determined by Nanodrop (ND-1000, Thermo Fisher, Waltham, MA).

Quantitative real-time polymerase chain reaction (qRT-PCR) {#Sec9}
----------------------------------------------------------

For cDNA synthesis, 0.5 μg total RNA from each pellet culture (3 with EMF treatment and 3 without treatment for each patient) was reverse-transcribed using the QuantiTect Reverse Transcription Kit (Quiagen, Hilden, Germany). QRT-PCR was performed using a LightCycler 96 System (Roche Diagnostics, Mannheim, Germany). Each reaction contained 5 μL of FastStart Essential DNA Green Master Mix (Roche Diagnostics, Mannheim, Germany), 2.5 μl of 1:3 diluted cDNA and 0.3 μl (300 nM), for test genes or 0.5 μl (500 nM), for reference gens of primer in a 10 μl final volume.

The following primers were used: Glycerinaldehyd-3-phosphat-dehydrogenase (*GAPDH*) \[[@CR19]\], collagen type II α~1~ chain (*COL2A1*) \[[@CR20]\], collagen type 1 α~1~ chain (*COL1A1*) \[[@CR21]\], cartilage-specific proteoglycan core protein (*ACAN*) \[[@CR20]\] and SRY (sex determining region Y)-box 9 (*SOX9*) \[[@CR20]\] (Table [2](#Tab2){ref-type="table"}).Table 2Gene sequences of primer pairs and annealing temperaturesGeneSequenceAnnealing temperatureGAPDH forwardTGC ACC ACC AAC TGC TTA GC60 °CGAPDH reverseGGC ATG GAC TGT GGT CAT GAG60 °CCOL2A1 forwardGTT ATC GAG TAC CGG TCA CAG AAG65 °CCOL2A1 reverseAGT ACT TGG GTC CTT TGG GTT TG65 °CACAN forwardCAG CAC CAG CAT CCC AGA65 °CACAN reverseCAG CAG TTG ATT CTG ATT CAC G65 °CCOL1A1 forwardTGA CCT CAA GAT GTG CCA CT65 °CCOL1A1 reverseACC AGA CAT GCC TCT TGT CC65 °CSOX9 forwardAGA CCT TTG GGC TGC CTT AT60 °CSOX9 reverseTAG CCT CCC TCA CTC CAA GA60 °C

Thermal cycling parameters included a denaturation step for 10 min,40 cycles of 95 °C for 10 s, 60 °C /65 °C for 10 s and 72 °C for 15 s. Reactions for each pellet were performed in triplicate and the mean of relative quantification values was calculated by using the delta-delta Ct method \[[@CR22]\] with *GAPDH* as the reference gene. Box-plots (Fig. [3](#Fig3){ref-type="fig"}) of cartilage specific genes and *COL1A1* were established by normalizing qRT-PCR data of pellets with 5 and 8 mT EMF treatment to the mean of control pellets without EMF treatment.Fig. 3Alteration of normalized gene expression of COL2A1 (**a**), COL1A1 (**b**), ACAN (**c**) and SOX9 (**d**) to GADPH expressed by pellets of OA (*n* = 12 with 5 mT and *n* = 9 with 8 mT) and non-OA patients (*n* = 9 with 5 mT and 8 mT) after 7 days in a 5 mT or 8 mT EMF normalized to the respective control group without (0 mT) EMF exposition

Statistical analysis {#Sec10}
--------------------

All RNA variables were described graphically by box-and-whisker plots and numerically using appropriate measures of location and dispersion. Due to the positive skew of their distributions of our outcome variables, we used the decadic logarithms instead of the original values as dependent variables in our models. The appropriateness of the log transformation was checked graphically using the residual plots for the resulting models. The effects of diagnosis, electromagnetic field strength, and their interaction with the log-transformed outcome variables were explored by means of mixed effects model with a random intercept per patient using the MIXED procedure of the Statistical Analysis System SAS, version 9.4 for Windows (SAS Institute, Cary, NC, USA). *P* \< 0.05 were regarded as statistically significant.

Results {#Sec11}
=======

Histology and immunohistochemistry {#Sec12}
----------------------------------

Positive staining for safranin-O and alcian blue were found in all pellet cultures. All pellet cultures showed signs of collagen type II and type I with differences in density. Representative images of pellet cultures are shown in Fig. [2](#Fig2){ref-type="fig"} with pellet sections from one OA patient cultured without EMF (Fig. [2a, e, i, m](#Fig2){ref-type="fig"}) and one cultured with 5 mT EMF (Fig. [2b, f, j, n](#Fig2){ref-type="fig"}). Figure [2](#Fig2){ref-type="fig"} also shows pellet sections from one non-OA patient cultured without EMF (Fig. [2c, g, k, o](#Fig2){ref-type="fig"}) and one with EMF 5 mT (Fig. [2d, h, l, p](#Fig2){ref-type="fig"}).

Comparing pellet cultures of non-OA to OA chondrocytes, non-OA cultures showed a more homogenous and compact structure than pellets from OA chondrocytes. A stronger staining for collagen type I was observed in OA cultures (Fig. [2m](#Fig2){ref-type="fig"}, n). OA cultures treated with specific 5 mT EMF showed a similar staining for collagen type II to non-OA cultures (Fig. [2j, k, l](#Fig2){ref-type="fig"}) whereas untreated OA pellets showed less staining for collagen type II (Fig. [2i](#Fig2){ref-type="fig"}).

OA pellets treated with 8 mT showed no differences in staining compared to the control OA group without EMF (data not shown).

No differences in staining intensity for collagen type II and collagen type I were found for pellet cultures of non-OA chondrocytes which had been treated with EMF (5 mT/8 mT) versus the control non-OA group (5 mT data in Fig. [2](#Fig2){ref-type="fig"}; 8 mT data not shown).

Visual histological grading {#Sec13}
---------------------------

Table [1](#Tab1){ref-type="table"} shows results of the visual histological grading system. Pellets from OA patients with 5 mT EMF treatments had a higher score in category A and B than in the OA control group without EMF treatment. The pellets from OA patients treated with 5 mT EMF did not reach the scores from pellets of non-OA patients. OA pellets treated with 8 mT showed the same score as the untreated controls. Pellets from non-OA patients showed no difference in all three categories (0 mT/5 mT/8 mT) and presented the best cartilage-like cell morphology with strong staining for collagen type II, formation possessed the rounded morphology typical of chondrogenic cells and are surrounded by an extracellular matrix (Table [1](#Tab1){ref-type="table"}).

Quantitative real-time PCR {#Sec14}
--------------------------

All pellet cultures from OA patients and non-OA patients expressed the cartilage specific markers *COL2A1*, *ACAN* and *SOX9* mRNA and the unspecific *COL1A1* mRNA (Fig. [3a-d](#Fig3){ref-type="fig"}).

OA cultures from the 5 mT EMF treatment group presented with significantly higher expression (*p* \< 0.001) of COL2A1 and ACAN (*p* \< 0.01) than the OA control group with 0 mT EMF treatment (Fig. [3a](#Fig3){ref-type="fig"}, c). In contrast, no changes in gene expression were observed in pellets from non-OA patients.

OA cultures treated with 8 mT EMF showed also no significant differences in gene expression compared to OA control cultures with 0 mT EMF treatments (Fig. [3a-d](#Fig3){ref-type="fig"}).

No significant changes in gene expression were observed for pellets from non-OA patients treated with or without 8 mT EMF (Fig. [3a-d](#Fig3){ref-type="fig"}).

Discussion {#Sec15}
==========

Effects of 5 mT and 8 mT EMF on OA and non-OA chondrocytes were examined in a 3D culture system. The 5 mT EMF increased *COL2A1* and *ACAN* gene expression of OA chondrocytes. The 8 mT EMF did not show any effects on OA and non-OA chondrocytes gene expression. The effects of EMFs on chondrocytes are inconsistent in the literature \[[@CR4], [@CR23]\]. A specifically beneficial EMF is difficult to characterize as in the literature electromagnetic fields with a broad range of intensity have been used in similar settings. EMFs in the range from 0.5 up to 5 mT seem to generate positive results on cartilage \[[@CR11]\]. Within this study a 5 mT EMF, which had previously been shown to exert beneficial effects on the chondrogenic differentiation of hMSCs \[[@CR12]\], was examined versus an EMF of 8 mT. No effects of the 8 mT EMF on gene expression was observed in OA nor in non-OA chondrocytes. It can therefore be postulated that although there is a field spectrum for beneficial effects of EMF on cartilaginous cells, it is possible to reduce EMF effects by slight adjustments to electromagnetic field.

As EMF effects depend very much on multiple parameters including frequency, magnetic field peak amplitude as well as exposure length \[[@CR24]\] we were interested whether EMF effects also vary with on cell quality. To our knowledge, studies comparing EMF effects on human OA to non-OA cartilage are lacking. In previous published studies EMFs were applied to OA cartilage explants, where they were shown to increase proteoglycan synthesis after 7 days \[[@CR7]\]. EMF effects were also examined in bovine articular cartilage explants, where an EMF (2.3 mT, 60 Hz), increased proteoglycan synthesis both under basal conditions and in the presence of interleukin-1 \[[@CR24]\]. Positive effects of 1, 2 and 3 mT 60 Hz EMFs on the expression of cartilage specific genes and glycosaminoglycan synthesis were also observed in non-OA bovine chondrocytes \[[@CR8]\]. When particular parameters were used, EMFs were even able to prevent degenerative changes in cartilage explants with a potency almost reaching low-intensity pulsed ultrasound research \[[@CR25]\].

During this study EMF effects on human OA and non-OA chondrocytes were cleary divergent. The application of 5 mT EMF resulted in an upregulation of *COL2A1* and *ACAN* gene expression in OA chondrocytes. In contrast to OA chondrocytes, non-OA chondrocytes did not seem to significantly profit from EMF.

Previoussimilar results were shown in a study of hMSCs where EMF effects were only observed under suboptimal cell culture conditions and EMF effects were dependent on the cellular quality of the hMSCs \[[@CR12]\]. Why EMF stimulation is mainly effective in degenerated or suboptimal chondrogenic cells remains to be answered. Variable reasons are possible to explain the stronger influence of EMF on degenerated chondrocytes.

Regarding the pathogenesis of OA adenosine receptors (ARs), A~2A~ and A~3~ play an important role in the anti-inflammatory pathway by decreasing expression of nuclear factor κB (NF-κB) a transcriptional factor of inflammatory cytokines such as interleukin-1 beta (IL-1ß), interleukin-6 (IL-6) and tumornecrosis factor alpha (TNF-α) \[[@CR26]\]. EMFs have been described to increase anti-inflammatory effects by inducing up-regulation of A~2A~ and A~3~ ARs \[[@CR27], [@CR28]\].

An other mechanism for a re-improvement of chondrogenic potential through EMF may be increased growth factor synthesis \[[@CR29]\]. EMFs act on transforming growth factor beta 1 (TGF-β~1~) -growth factor release and may thereby restore the chondrogenic potential of degenerated or suboptimal chondrogenic cells. In addition, EMFs may have anti-apoptotic effects by decreasing the expression of proteins involved in the pro-apoptotic pathway and simultaneously increasing expression of anti-apoptotic proteins \[[@CR30]\]. EMF treatment seems to improve suboptimal or degenerate cellular conditions for chondrocytes \[[@CR31], [@CR32]\]. In the absence of chondrocyte stress EMFs may be ineffective which may in part explain the lack of EMF effect in some studies. It also needs to be evaluated whether degeneration of tissue or the age of the donor are responsible for the EMF effects. For general statements about degeneration and EMF effects, further studies are necessary to clearly define this mechanism.

Conclusions {#Sec16}
===========

The application of 5 mT EMFs has a positive effect on degenerated OA chondrocytes by increasing expression of *COL2A1* and *ACAN*. The effect of 5 mT EMFs on non-OA chondrocytes is markedly less pronounced. 8 mT EMF did not exert an effect on OA or on non-OA chondrocytes. Further studies are necessary to evaluate EMF effects in different settings, which may be a valuable tool in treating OA patients.
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